13F-HR filed by Caligan Partners LP
Caligan Partners LP filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 18 holding rows worth $763,509,272.
- Accession
- 0001420506-25-003441
- Filer
- CIK 1727492
- Filed
- 2025-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 18 entries on the cover page, a total value of $763,509,272 stated on the cover page (in dollars after the unit check, H1), rows summing to $763,509,272 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 8,118,892 | $184,623,604 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 1,451,924 | $123,268,348 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 2,772,654 | $105,139,040 | dollars as filed | |
| EXELIXIS INC COM | 30161Q104 | Stock | 1,525,730 | $63,012,649 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 1,064,249 | $49,700,428 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 1,131,205 | $45,406,569 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 975,000 | $39,136,500 | dollars as filed | put |
| ADMA BIOLOGICS INC | 000899104 | COM | 2,636,609 | $38,652,688 | dollars as filed | |
| EVOLUS INC | 30052C107 | COM | 4,138,943 | $25,413,110 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 216,954 | $20,426,219 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 444,565 | $17,849,285 | dollars as filed | |
| ANIKA THERAPEUTICS INC | 035255108 | COM | 1,435,130 | $13,490,222 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 833,333 | $10,591,662 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 696,825 | $9,748,582 | dollars as filed | |
| INHIBRX BIOSCIENCES INC | 45720N103 | COM | 236,383 | $7,961,379 | dollars as filed | |
| VERRICA PHARMACEUTICALS INC | 92511W207 | COM SHS | 923,910 | $3,982,052 | dollars as filed | |
| SELLAS LIFE SCIENCES GROUP I | 81642T209 | COM NEW | 2,300,000 | $3,703,000 | dollars as filed | call |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 227,174 | $1,403,935 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001420506-25-003441 | this filing | 2025-11-14 | acceptance time not in the bulk data set |